Ardelyx, Inc. (NASDAQ:ARDX) ranks fourth on the list of best biotech stocks, focusing on gastrointestinal and cardiorenal disease therapies. It reported record Q2 2025 revenues of $97.7 million, with strong sales growth for IBSRELA and XPHOZAH. The company raised its 2025 sales guidance, indicating robust market uptake and investor confidence.

Ardelyx, Inc. (ARDX) strengthens its global presence through a partnership with Kyowa Kirin, expanding the reach of its treatments. While current growth is driven by IBSRELA and XPHOZAH, the company continues to invest in R&D for gastrointestinal and related conditions with unmet medical needs.

While Ardelyx, Inc. (NASDAQ:ARDX) shows promise as an investment, some AI stocks may offer greater upside potential with less downside risk. For those seeking undervalued AI stocks benefiting from current economic trends, consider exploring our free report on the best short-term AI stock.

Read more at Yahoo Finance: Ardelyx, Inc. (ARDX) Strengthens Global Reach with Kyowa Kirin Deal